4.20
+0.48%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Opus Genetics
From its filings with the US Securities and Exchange Commission
Opus Genetics is based in Durham, North Carolina and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker IRD. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $14.2m and a net loss of $49.6m. At that date it held total assets of $50.2m and shareholders' equity of $15.3m.
In April 2018, Ocuphire Pharma, Inc. merged with Ocularis Pharma, LLC, the original innovator of phentolamine mesylate ophthalmic solution.
In January 2020, Ocuphire Pharma, Inc. obtained from Apexian Pharmaceuticals, Inc. certain rights to its Ref-1 inhibitor program, including APX3330.
Our treatments are administered via subretinal injection, a proven and reliable delivery method that allows us to directly target the location of disease in the retina.
Our gene therapy programs address mutations in genes that cause different forms of Leber congenital amaurosis, bestrophinopathy, and retinitis pigmentosa.
The LCA5 gene encodes for the protein lebercilin, a ciliary protein which is critical for bidirectional protein trafficking in photoreceptor inner and outer segments.
Encoded by the RHO gene, rhodopsin is an important component of the photopigment in rod photoreceptors that absorbs light and provides structure to the rod outer segments.
Autosomal dominant mutations in rhodopsin cause RHO-adRP, which is characterized by progressive death of the rod photoreceptors that can lead to vision loss.
Quoted from its 10-K, filed 12 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 30 Nov 2004
- Employees
- 27
- Website
- ocuphire.com ↗
- Head office
- 8 DAVIS DRIVE, DURHAM, NC, 27713
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Mr. Cam GallagherIndependent Chairman of the Board$174,620
- Dr. Benjamin YerxaPresident, Director, since 2024
- Dr. George MagrathChief Executive Officer, Director, since 2023$2.7m
- Mr. Robert GagnonChief Financial Officer, Principal Accounting Officer
- Mr. Joseph SchachleChief Operating Officer
- Mr. Bernhard HoffmannSenior Vice President - Corporate Development and Operations$789,918
- Dr. Ash JayagopalChief Scientific and Development Officer
- Mr. Ronil PatelChief Business Officer$1.1m
- Dr. Jean BennettDirector
- Mr. Sean AinsworthIndependent Director$149,562
- Ms. Susan BentonIndependent Director$135,341
- Dr. James ManusoIndependent Director$154,806
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Ocuphire Pharma focuses on ophthalmic biopharmaceutical products with two pipeline candidates targeting refractive and retinal eye disorders.
- Nyxol Eye Drops is a once-daily formulation for reducing pupil diameter and improving visual acuity across multiple indications.
- APX3330 is a twice-a-day oral tablet targeting multiple pathways for retinal and choroidal diseases.
Weaknesses
- Ocuphire Pharma has only 9 full-time employees in Farmington Hills, Michigan, limiting operational capacity.
- The company's IPO on 30 November 2004 indicates a long history without significant recent growth.
- Nyxol Eye Drops and APX3330 are still in development without approved commercial products.
Opportunities
- The ophthalmic biopharmaceutical market offers potential for Nyxol Eye Drops to address refractive and retinal disorders.
- APX2009 and APX2014 represent second-generation product candidates with expanded therapeutic potential.
- Farmington Hills, Michigan, provides a strategic location for research and development in the Health Care sector.
Threats
- Ocuphire Pharma faces competition from established pharmaceutical companies in the Health Care sector.
- The lack of approved products may delay revenue generation and market entry.
- Regulatory approvals for Nyxol Eye Drops and APX3330 could face delays or rejections.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.